Outpatient Infusion


REMICADE (also known as Infliximab)


Remicade is an antibody that binds and inhibits tumor necrosis factor alpha (TNFα).  Because TNFα is core chemical messenger in inflammation, Remicade has been found to be effective in treating many autoimmune conditions.


  • Active, moderate-to-severe Crohn’s Disease
  • Active, moderate-to-severe Ulcerative Colitis
  • Active, moderate-to-severe Rheumatoid Arthritis in conjunction with Methotrexate
  • Symptomatic ankylosing spondylitis
  • Symptomatic psoriatic arthritis
  • Severe plaque psoriasis


Patients with active infection should not be started on Remicade.  Patients with history of heart failure, cancer, and Hepatitis B should consult with their physician prior to starting Remicade.


Remicade is typically administered as an infusion at week 0, 2, 6 and every 8 weeks thereafter.

Copyright by Thrivewell 2017. All rights reserved.